Publications from the National Academies of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes Health and Medicine Division (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Advancing Therapeutic Development for Pain and Opioid Use ...
Released: March 23, 2018
Chronic pain is one of the most prevalent, costly, and disabling health conditions in the United States. In parallel with increasing recognition of the need to treat chronic pain, the opioid epidemic has emerged as a growing public health emergency. In 2017, the National Institutes of Health began exploring public-private partnerships to develop solutions to the opioid crisis and cut in half the time it takes to develop non-addictive analgesics. To help inform this effort, the National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a public workshop that brought together experts and stakeholders from academia, federal agencies, advocacy organizations, and companies developing therapeutics for pain and opioid use disorders.
Implementing and Evaluating Genomic Screening Programs ...
Released: March 16, 2018
Genomic applications are being integrated into a broad range of clinical and research activities at health care systems across the United States. The genomics-based screening programs are clinical screening programs that examine genes or variants in unselected populations in order to identify individuals who are at an increased risk for a particular health concern (e.g., diseases, adverse drug outcomes) and who might benefit from clinical interventions.
Enabling Novel Treatments for Nervous System Disorders by ...
Released: March 08, 2018
The blood-brain barrier (BBB) presents a special challenge to the development of therapeutics for many central nervous system (CNS) disorders. Far from acting simply as a physical barrier, the BBB is a complex dynamic system involving several cell types, passive and active transport mechanisms, and adaptive function to control the exchange of substances between the blood and the CNS. Few therapeutic agents readily traverse the BBB to reach the brain or spinal cord, including most small molecule drugs and the vast majority of large molecules such as proteins.
Examining the Impact of Real-World Evidence on Medical ...
Released: February 12, 2018
Randomized, controlled clinical trials (RCTs) have traditionally served as the gold standard for evidence generation in support of medical product development and evaluation. However, it is increasingly recognized that RCTs have inherent limitations, particularly with regard to generalizability, and time and monetary investment. Data from sources supplemental to RCTs, such as safety surveillance, observational studies, registries, claims, or patient-centered outcomes research, would be valuable to support biomedical research, including medical product development and evaluation.
Review of NASA's Evidence Reports on Human Health Risks ...
Released: January 10, 2018
The National Academies of Science, Engineering and Medicine, at the request of the National Aeronautics & Space Administration (NASA) and with guidance from the National Academies’ Standing Committee on Aerospace Medicine and the Medicine of Extreme Environments, established a committee to review NASA’s Evidence Reports on Human Health Risks. These evidence reports focus on human health risks for long-duration and exploration spaceflights.
Incorporating Weight Management and Physical Activity ...
Released: December 01, 2017
The National Cancer Policy Forum held a public workshop in February 2017 to examine the potential for weight management and physical activity interventions to improve health outcomes for cancer survivors. The workshop, Incorporating Weight Management and Physical Activity throughout the Cancer Care Continuum, highlighted the current evidence base, gaps in knowledge, and research needs on the associations among obesity, physical activity, weight management, and health outcomes for cancer survivors.
Navigating the Manufacturing Process and Ensuring the ...
Released: October 26, 2017
Regenerative medicine holds the potential to create living, functional cells and tissues which can be used to repair or replace those that have suffered irreparable damage due to disease, age, traumatic injury, or congenital defects. Although regenerative medicine has the potential to result in health and economic benefits, this relatively new field faces unique manufacturing and regulatory challenges in the development of novel therapies that are both safe and effective. Some of these issues arise because regenerative medicine therapies produce and rely on living cells and tissues, which are inherently variable, even within a single type of cell.
Examining Challenges and Possible Strategies to Strengthen ...
Released: October 18, 2017
As the United States continues to adapt to a more digital, mobile, and interconnected world, health care and public health professionals have sought to better prepare for and respond to long-standing and emerging threats to the nation’s health security. Health security is the collective effort to prevent, protect against, mitigate, respond to, and recover from the health consequences of natural, man-made, and technological disasters.
Opportunities for Organ Donor Intervention Research: Saving ...
Released: October 10, 2017
The organ donation and transplantation system strives to honor the gift of donated organs by fully using those organs to save and improve the quality of the lives of their recipients. While most related research to date has focused on improving transplantation processes and health outcomes for recipients, the field of organ donor intervention research looks at ways to enhance the quality and increase the quantity of organs that can be recovered from deceased donors and then successfully transplanted.
Biomarkers of Neuroinflammation: Proceedings of a Workshop ...
Released: September 15, 2017
Innate and adaptive immunity have become very important areas of investigation for psychiatric, neurologic, and neurodevelopmental disorders, and neurodegeneration resulting from traumatic brain injury. To address these gaps in understanding mechanisms and how to translate that understanding into therapeutics, the Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine convened a workshop on March 20–21, 2017, bringing together key leaders in the field from industry, academia, and governmental agencies to explore the role and mechanisms of neuroinflammation in a variety of central nervous system diseases.